Embryotoxic Effects of Atorvastatin on Mouse Fetus Embryo toxicity of atorvastatin
Iranian Journal of Pharmaceutical Sciences,
Vol. 9 No. 1 (2013),
6 February 2024
,
Page 13-23
https://doi.org/10.22037/ijps.v9.40909
Abstract
Although the biokinetics, metabolism, and chemical toxicity of atorvastatin calcium are well known, until recently little attention was paid to the potential toxic effects of atorvastatin calcium on re-production and development in mammals. In recent years, it has been shown that atorvastatin calcium is a developmental toxicant given orally or subcutaneously (SC) to mice. Decreased fertility, embryo/fetal toxicity including teratogenicity, and reduced growth of the offspring have been observed following atorvastatin calcium exposure at different gestation periods. On the other hand, an in vitro study using fetal isolated mitochondria nowadays has been recognized as a confident tool to evaluate the developmental toxicity of a number of chemicals. Although the developmental toxicity induced by atorvastatin has been investigated, the precise cellular mechanism of atorvastatin -induced embryo-toxicity has not been thoroughly recognized yet. For investigating the effects of atorvastatin calcium on pregnant animals, three groups (control, sham and test) of NMRI mice were chosen. In test group,50mg/kg,100mg/kg and 150mg/kgof atorvastatin calcium were intraperitonealy administered at 11 day of gestation, in sham group only normal saline injected to interior peritoneum as indicated in the test group and in Control group which was considered as the comparison base line of our research, no injection was made. Caesarean sections were performed at 15 day of the gestation; and their placentas were examined externally. Based on our results atorvastatin calcium caused significant external anomalies, and caused a significant decrease (p<0.001) in the weight and diameter of placentas, the number of the embryos, their body weight and crown-rump length of fetuses.
- Atorvastatin calcium
- Embryotoxicity
- Liver enlargement
- Morphological anomalies
- Umbar vertebrae
How to Cite
References
[2] Kazmin A, Garcia-Bournissen F, Koren. Risks of Statin Use during Pregnancy: A Systematic Review. J Obstet Gynaecol Can 2007; 29(11):906–908.
[3] Topol EJ. Intensive statin therapy—a sea changes in cardiovascular prevention. N Engl J Med 2004; 350:1562–4.
[4] Henck JW, Craft WR, Black A, Colgin A, Ander son JA. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci 1998; 41:88–99.
[5] Hrab RV, Hartman HA, Cox RH. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid sup plementation. Teratology 1994; 50:19–29.
[6] Sandoz Canada Inc, Astra Pharma Inc. Pharmacokinetics. In: Product monograph. Lescol: fluvas tatin sodium. Dorval, Que, Mississauga, Ont: Sandoz Canada Inc. Astra Pharma Inc 1993:1–11.
[7] Minsker DH, MacDonald JS, Robertson RT, Bokelman DL. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of me vinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Teratology 1983; 28:449–56.
[8] Wise LD, Prahalada S, Robertson RT, Bokelman DL, Akutsu S, Fujii T. Simvastatin (MK-0733) oral teratogenicity study in rabbits. Yakuri to Chiryo 1990; 39(2):159–67.
[9] Minsker DH, Robertson RT, Bokelman DL. Simvastatin (MK-0733): oral late gestation and lactation study in rats. Yakuri to Chiryo 1990; 39(2):169–79.
[10] Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10(6):439–46.
[11] Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 1994; 50(6):387–94.
[12] Di Renzo F, Broccia ML, Giavini E, Menegola E. Antifungal triazole derivative triadimefon induces ectopic maxillary cartilage by altering the morphogenesis of the first branchial arch, Birth Defects Res B Dev. Reprod Toxicol 2007; 80: 2–11.
[13] Taguchi N, Rubin E T, Hosokawa A, Choi J, Ying A Y, Moretti M E., Shinya Ito G K. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26: 175–177.
[14] Totori-Donati P, Rossi A, Biancheri, R. In C. Pediatric Neuroradiology: Brain, Head, Neck and Spine, Brain Malformations; Totori-Donati, Paolo; Rossi, Andrea; Raybaud, Springer, 2005; pp, 92–95.
[15] Edison R J, Muenke M. Central nervous system and limb anomalies in case reports of first trimester statin exposure. New England Journal of Medicine 2004 ; 350: 1579-1582.
- Abstract Viewed: 408 times
- IJPS_Volume 9_Issue 1_Pages 13-23 Downloaded: 276 times